A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in Germany
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
1estimated
Sites
1
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-02 | actual | When the study began enrolling |
| Primary completion | 2026-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
Intervention
- Other: tafamidis 61mg (based on prescription data)
Primary outcomes
what the primary-completion date above is the date OFOverall Survival in Individuals With Incident Transthyretin Amyloid Cardiomyopathy (ATTR-CM), Overall and in Those With at Least One Tafamidis Prescription
measured From incident ATTR-CM diagnosis (Index 1) until death, end of SHI enrollment, or end of data availability (December 31, 2023). For those with at least one tafamidis prescription, additionally from first tafamidis prescription (Index 2).
Cardiovascular-Related Hospitalizations in Individuals With Incident Transthyretin Amyloid Cardiomyopathy (ATTR-CM), Overall and in Those With at Least One Tafamidis Prescription
measured From incident ATTR-CM diagnosis (Index 1) until death, end of SHI enrollment, or end of data availability (December 31, 2023). For those with at least one tafamidis prescription, additionally from first tafamidis prescription (Index 2).
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed